We launched Fulcrum Therapeutics with a bold vision: To change the course of genetically defined diseases by treating them at their root cause.
Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively about the best way to modulate and balance gene expression. The result: FulcrumSeek, a patient-focused product engine designed to systematically identify and validate cellular drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. We take great pride in being purposeful patient partners who do this work, not just for patients, but with patients. We have a culture of trust and transparency which enables our employees to focus on our mission and the science behind it. In addition, we are invested in our people and want to ensure they have the tools and training they need to succeed. This allows our playful spirit to come alive, making work more enjoyable for our entire Fulcrew.
Judith Dunn, Ph.D.
Judith Dunn, Ph.D. joined Fulcrum in April 2021 as president, research & development. In her career she has held leadership roles in all phases of drug development from discovery through commercialization. Most recently, Judy served as entrepreneur in residence at Atlas Venture, where she led the formation of new companies positioned to address areas of unmet need in neuroscience. She is currently an independent board director at Evolution Research Group and a member of the NYC Mayor’s Advisory Council on Life Sciences. Previously, Judy served as vice president of clinical development at Roche in Basel, Switzerland and head of the Roche Innovation Center in NYC. While in New York, she participated in the establishment of the Empire Discovery Institute, a NY State effort to catalyze the progression of academic discovery research to clinical application. She has held positions in both the research and commercial divisions of Pfizer and led clinical programs in psychiatry at Sunovion (Sepracor). Judy received a postdoctoral fellowship in clinical research from Pfizer and a training fellowship in neuropharmacology from the Center for Brain Research at Strong Memorial Hospital. She earned her undergraduate degree in neuroscience at University of Rochester and her graduate degree in neurobiology at Wesleyan University.
Christopher Moxham, Ph.D.
Chris Moxham, Ph.D. joined Fulcrum in January 2019 as senior vice president of Discovery Research before being promoted to chief scientific officer in January 2021. He has more than two decades of experience in drug discovery. Prior to joining Fulcrum, Chris worked at Eli Lilly and Company where he helped grow the organization’s oncology pipeline, developed critical biopharma and academic partnerships and established a state-of-the-art laboratory facility focused on preclinical and translational research. He has led teams that have delivered numerous small and large molecules into clinical development. Chris serves on the external review boards of the Long Island Bioscience Hub and the Alzheimer’s Drug Discovery Foundation. He earned his B.S. in biological sciences from Cornell University and his Ph.D. in molecular and cellular pharmacology from the State University of New York at Stony Brook before conducting postdoctoral training at SUNY Stony Brook.
Pamela S. Strode
Nicole T. Gallagher
Nicole T. Gallagher is Director of Administration and Executive Assistant to the CEO at Fulcrum Therapeutics, where she leads management of a range of operational areas including internal and external communications, collaboration with patient communities and vendors, planning and execution of needs related to the company board of directors and strategies to develop and promote corporate culture, cross-team collaboration and team building. Prior to joining Fulcrum, Nicole’s 20-year career has included lead roles in administration at companies including Abcam, Tapestry Networks, Aviva Life Insurance and Enterprise Rent-A-Car. In her previous roles she has executed strategies to strengthen client, customer and employee relationships, managed and executed corporate global events, and overseen the daily administration of office operations. In healthcare industry settings she has also spearheaded efforts to help team members connect directly with patients, noting, “To see and hear directly from patients tells us what we’re working towards and makes it more real.”
Curtis Oltmans, JD
Curtis Oltmans, JD joined Fulcrum as General Counsel in November 2020 with over 25 years of experience in
corporate law including senior management positions in legal departments at several leading
pharmaceutical and biotechnology companies. He most recently served as Vice President, Head of
Litigation at DaVita Kidney Care, Inc. where he led a 30-person team and was responsible for all
litigation, workers’ compensation and employee safety matters. Prior to DaVita, Curtis was Executive
Vice President, General Counsel and Corporate Secretary at Array BioPharma Inc. where he oversaw all
legal, corporate governance, patent and compliance matters. He previously served as Corporate Vice
President and General Counsel for Novo Nordisk, Inc., North America where he was responsible for
strategic support in areas including market access, government affairs, communications and product
marketing. He has also served as Assistant General Counsel for Eli Lilly and Company after beginning his
legal career supporting clients in pharmaceutical and medical device litigation matters. Curtis received a
BA in political science from the University of Nebraska and his JD from the University of Nebraska
College of Law.
Christopher Morabito, MD
Chris Morabito, MD has extensive leadership experience at biotechnology and pharmaceutical companies and has advanced discovery and clinical programs including Phase 1, proof-of-concept and pivotal studies. Most recently, he served as chief medical officer at Cardurion Pharmaceuticals where he oversaw all drug development activities. Prior to Cardurion, he served in several roles at Takeda, including program leadership and head of pipeline strategy, most recently serving as senior vice president and head of research and development for plasma-derived protein therapies. He also led programs from early development stage through regulatory submission at Sanofi and he began his career in industry at Merck & Co, leading development of multiple cardiovascular assets. Chris was also chief of the division of neonatology at Lehigh Valley Hospital and Health Network. He trained initially as a neonatologist at the University of California, San Francisco. He earned his B.A. in biology from Franklin and Marshall College, and his M.D. from Penn State University College of Medicine.
Mani Sundararajan, Ph.D.
Mani Sundararajan, Ph.D., joined Fulcrum in July 2021 as senior vice president, technical operations. Most recently he worked at Seagen, where he led several technical operations functions including small molecules process development, CMC strategy and program management. He has also held leadership positions in drug development and technical operations at Takeda, Shire, AstraZeneca, Bristol-Myers Squibb and DuPont Pharmaceuticals. Mani has a B.Sc.(Tech.) in pharmaceuticals & fine chemicals technology from the Institute of Chemical Technology at University of Mumbai, India, an M.S. and Ph.D. in pharmaceutical sciences from Temple University, and an executive masters in technology management from University of Pennsylvania’s School of Engineering & Applied Science and Wharton.
Mel Hayes joined Fulcrum Therapeutics in September 2021 as chief commercial officer, bringing more than 25 years of experience in development and management of commercialization strategies in a range of therapeutic areas including many rare and specialty diseases. At Fulcrum he is responsible for leading the company’s commercial strategies and operations, including marketing, sales, new product planning, business analytics, and patient engagement. Prior to Fulcrum, Mr. Hayes most recently served as global head commercial, vice president, rare blood disorders at Sanofi-Genzyme, where he led the commercial organization for hemophilia and complement assets. He also served as U.S. vice president hemophilia and global head, hematology rare blood disorders at Bioverativ (acquired by Sanofi-Genzyme). He was formerly global vice president, head of global marketing and launch excellence at Shire and was global vice president hemophilia at Baxalta (acquired by Shire). He also spent 10 years at Bayer and nine years at Bristol Myers Squibb in progressive leadership roles where he was responsible for launching products in diabetes, cardiovascular disease, neurology, rheumatology, multiple sclerosis and Parkinson’s disease. He earned dual bachelor’s degrees in business and communications from Southern Methodist University and an MBA from Columbia University.